Dexrazoxane warrants further investigation for its cardioprotective action against anthracycline cardiotoxicity beyond simple iron chelation.
Answers are grounded in this paper and cite their sources.
Challenges iron chelation as sole mechanism; leaves open redox-based cardioprotection strategies in anthracycline-treated patients.
Dexrazoxane may be the key to the enigma of anthracycline cardiotoxicity, and therefore it warrants further investigation, including the search for alternative/complementary modes of cardioprotective action beyond simple iron chelation.
No takes yet. Share an insight, caveat, or question.
Štěrba et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: